NRX Pharmaceuticals, Inc. 10-Q

Item 5. Other Information None. ​ 54 Table of Contents Item 6. Exhibits Exhibit Number Description ​ ​ ​ 10.1+ ​ Amendment to Convertible Promissory Note, dated June 30, 2023, by and between NRx Pharmaceuticals, Inc. and Streetervillle Capital LLC. ​ ​ ​ 31.1+ ​ Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ​ ​ ​ 31.2+ ​ Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ​ ​ ​ 32.1+† ​ Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ​ ​ ​ 32.2+† ​ Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ​ ​ ​ 101* ​ Interactive data files pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022; (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022 ; (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the nine months ended September 30, 2023 and 2022; (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022; and (v) Notes to Unaudited Financial Statements. ​ ​ ​ 104 ​ Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101) ​ + Filed herewith. † This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. * In accordance with Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, is deemed not filed for purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections. 55 Table of Contents SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized ​ ​ ​ ​ ​ ​ ​ NRX PHARMACEUTICALS, INC. ​ ​ ​ Date: November 14, 2023 ​ By: /s/ Richard Narido ​ ​ ​ Richard Narido ​ ​ ​ Chief Financial Officer (Principal Financial Officer) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 56